Michael Reilly: Forcing patients to switch to biosimilars puts them in uncharted waters MICHAEL REILLY Updated: June 24, 2019 On May 27, the B.C. government announced a policy that will forcibly switch thousands of patients, effective Nov. 22, with serious, chronic conditions from their current biologic medicines to lower-cost “biosimilar” treatments. The roughly 23,000 patients […]
From June 4th-6th, ASBM exhibited at the 2019 BIO International Convention held in Philadelphia, PA. Each year, the BIO International Convention attracts approximately 16,000 attendees from more than 5,000 companies and from 70 different countries. ASBM was represented at the booth by Andrew Spiegel, ASBM Steering Committee member and executive director of the Global Colon Cancer Association. At ASBM’s booth, attendees […]
ARLINGTON, Va., June 6, 2019 /PRNewswire/ — On May 27th, the Government of British Columbia (B.C.) announced a policy that will forcibly switch thousands of patients with serious, chronic conditions from their current biologic medicines to lower-cost “biosimilar” treatments, effective November 25th, 2019. The roughly 23,000 patients who will be affected include those with rheumatoid arthritis, plaque psoriasis, […]
